Sign Up to like & get
recommendations!
1
Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6000
Abstract: BACKGROUND Lymphocyte activation gene 3 (LAG-3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T-cell activation. Many clinical trials of LAG-3 inhibitors have had modest effects, but recent data…
read more here.
Keywords:
lag transcriptomic;
lag;
lag expression;
expression ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Immunology"
DOI: 10.1158/1538-7445.am2021-1625
Abstract: Background: Immune checkpoint inhibitors (ICIs) have become the standard of care in a range of tumors. However, a large proportion of patients treated with ICIs have treatment-refractory/resistant tumors requiring innovative approaches. Lymphocyte-activation gene 3 (LAG-3)…
read more here.
Keywords:
expression;
prevalence;
cancer;
lag ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e15086
Abstract: e15086Background: Concomitant blockade of LAG-3 and PD-1 has been shown to restore T-cell activation and enhance anti-tumor immunity in preclinical models. Clinical trials evaluating anti-LAG-3/ant...
read more here.
Keywords:
immunohistochemistry analyses;
tumor;
analyses lag;
expression ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.957208
Abstract: In pediatric Hodgkin lymphoma (HL), the inability of the cytotoxic microenvironment induced by EBV presence to eliminate tumor cells could reflect the fact that the virus might be able to induce the expression of exhaustion…
read more here.
Keywords:
hodgkin lymphoma;
pediatric hodgkin;
lag expression;
ebv associated ... See more keywords